Press releases – BioArctic

BioArctic outlicenses its alpha-synuclein antibody portfolio for Parkinson’s Disease to AbbVie after receiving clearance

December 14, 2018 - Regulatory press release

Stockholm, Sweden, December 14, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic and its partner AbbVie (NYSE: ABBV) have received U.S. ...

BioArctic to present at Jefferies 2018 London Healthcare Conference on November 15

November 13, 2018 - Other press release

Stockholm, Sweden, November 13, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will present at Jefferies 2018 London Healthcare Conference on November 15, at 4.40 ...

BioArctic is awarded grant from EU’s Horizon 2020 for participation in research consortium for better diagnostic tools and biomarkers for Parkinson’s

November 12, 2018 - Regulatory press release

Stockholm, Sweden, November 12, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has been awarded a grant from EU’s research and innovation program Horizon 2020. ...

Interim Report January – September 2018

November 8, 2018 - Regulatory press release

BioArctic reports strong BAN2401 Phase 2b results for Alzheimer patients. AbbVie exercises its option to a license for Parkinson’s projects

BioArctic presents Nomination Committee and publishes financial calendar 2019

November 6, 2018 - Regulatory press release

Stockholm, Sweden, November 6, 2018 – According to the resolution of the Annual General Meeting in BioArctic AB (publ) on May 15, 2018 the members of ...

BioArctic’s partner AbbVie exercises its option to license the alpha-synuclein antibody portfolio for Parkinson’s Disease

November 2, 2018 - Regulatory press release

Stockholm, Sweden, November 2, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received a Notice of Option ...

Invitation to presentation of BioArctic’s Interim Report for the period January – September 2018 on November 8, 2018

October 30, 2018 - Other press release

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – September 2018 on Thursday, November 8, 2018 at ...

BioArctic announces additional BAN2401 Phase 2b study results in early Alzheimer’s disease presented by Eisai at the 2018 CTAD conference

October 25, 2018 - Regulatory press release

Stockholm, Sweden, October 25, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) previously announced on July 6, 2018 the positive topline results from the clinical ...

BioArctic is granted a concept patent in Europe for the company’s strategy for disease-modifying treatment of Parkinson’s disease

October 21, 2018 - Regulatory press release

Stockholm, Sweden, October 21, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to ...

BioArctic: Eisai to present additional data from BAN2401 Phase 2b study in early Alzheimer’s disease and the presentation will be webcast live from CTAD

October 18, 2018 - Other press release

Stockholm, Sweden, October 18, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Eisai will present additional data on the anti-amyloid (Aβ) ...

BioArctic receives European patent protection for a medical device for treatment of patients with Complete Spinal Cord Injury

October 3, 2018 - Regulatory press release

Stockholm, Sweden, October 3, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to ...

BioArctic signs a research agreement with Brain Biomarker Solutions in Gothenburg AB to develop new diagnostics for Alzheimer’s disease

September 13, 2018 - Regulatory press release

Stockholm, Sweden, September 13, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has signed a research agreement with Brain Biomarker Solutions in Gothenburg AB (BBS). ...

BioArctic expands the research collaboration with Uppsala University concerning antibody-based diagnostic imaging of the brain in Alzheimer patients

September 3, 2018 - Regulatory press release

Stockholm, Sweden, September 3, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that the company has signed an expanded research collaboration agreement with ...

Interim Report January – June 2018

August 23, 2018 - Regulatory press release

Positive results of the BAN2401 Phase 2b study in early Alzheimer’s disease April – June 2018 Net revenues for the period amounted to SEK 52.3 ...

Invitation to presentation of BioArctic’s Interim Report for the period January – June 2018 on August 23, 2018

August 14, 2018 - Other press release

Stockholm, Sweden, August 14, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – June 2018 ...

BioArctic obtains exclusive rights to develop antibody treatments for Alzheimer’s disease from a research project jointly owned with Eisai

August 7, 2018 - Regulatory press release

Stockholm, Sweden, August 7, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has in collaboration with Eisai identified a completely new biological target, which provides ...

BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer’s disease presented at AAIC 2018

July 25, 2018 - Regulatory press release

Stockholm, Sweden, July 25, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced on July 6 the positive topline results from the clinical Phase ...

BioArctic: Late breaking Phase 2b study results of BAN2401 in Alzheimer’s disease will be webcast live from AAIC 2018 by Eisai

July 18, 2018 - Regulatory press release

Stockholm, Sweden, July 18, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B). As previously announced, the BAN2401 Phase 2b clinical study results will be presented ...

BioArctic receives regulatory approval in Finland for a clinical study in patients with Complete Spinal Cord Injury

July 10, 2018 - Regulatory press release

Stockholm, Sweden, July 10, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received approval by Fimea, the Finnish Medicines ...

BioArctic Announces Acceptance of BAN2401 Phase 2b Results for Oral Presentation at the AAIC 2018

July 10, 2018 - Regulatory press release

Stockholm, Sweden, July 10, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces today the results of the BAN2401 Phase 2b clinical study (ClinicalTrials.gov identifier ...

BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer’s Disease

July 6, 2018 - Regulatory press release

The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in early Alzheimer’s disease demonstrated statistically significant and dose-dependent slowing in ...

BioArctic announces changes in the Management Team effective September 1, 2018

June 27, 2018 - Regulatory press release

Stockholm, Sweden, June 27, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that professor Lars Lannfelt resumes his employment in the company as ...

BioArctic receives this year’s SwedenBIO Award

May 16, 2018 - Other press release

Stockholm, Sweden, May 16, 2018 – BioArctic AB today received the SwedenBIO Award 2018. The prize is awarded to a company that has distinguished itself by ...

Report from the Annual General Meeting in BioArctic AB (publ)

May 15, 2018 - Regulatory press release

BioArctic AB (publ) held its Annual General Meeting on Tuesday May 15, 2018. The following resolutions were adopted:

BioArctic extends the research collaboration with Uppsala University regarding new antibody technology

May 14, 2018 - Regulatory press release

Stockholm, Sweden, May 14, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has signed an extended research collaboration agreement with ...

Interim Report January – March 2018

April 26, 2018 - Regulatory press release

Continued progress of the project portfolio January - March 2018 Net sales for the period amounted to SEK 52.3 million (26.2) Operating profit amounted to SEK ...

Inclusion completed of patients with complete spinal cord injury in the first panel of BioArctic’s ongoing study

April 25, 2018 - Regulatory press release

Stockholm, Sweden, April 25, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the inclusion of patients with complete spinal cord injury in ...

BioArctic publishes the Annual Report for 2017

April 24, 2018 - Regulatory press release

Stockholm, Sweden, April 24, 2018 – BioArctic AB (publ.) (Nasdaq Stockholm: BIOA B) announced today that the Annual Report for the 2017 fiscal year has ...

NOTICE OF ANNUAL GENERAL MEETING IN BIOARCTIC AB (PUBL)

April 13, 2018 - Regulatory press release

The shareholders in BioArctic AB (publ), corporate identity number 556601-2679, (”the Company”) are hereby summoned to the Annual General Meeting to be held on Tuesday, ...

Invitation to presentation of BioArctic’s Interim Report January – March 2018 on April 26, 2018

April 12, 2018 - Other press release

Stockholm, Sweden, April 12, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – March 2018 ...

BioArctic receives regulatory approval in Norway for a clinical study in patients with Complete Spinal Cord Injury

March 21, 2018 - Regulatory press release

Stockholm, Sweden, March 21, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received approval by the Norwegian Medicines Agency ...

BioArctic receives patent protection in Japan for a medical device for treatment of patients with Complete Spinal Cord Injury

March 19, 2018 - Regulatory press release

Stockholm, Sweden, March 19, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the Japanese Patent Office (JPO) issued a notification to grant ...

BioArctic receives regulatory approval in Estonia for a clinical study in patients with Complete Spinal Cord Injury

February 21, 2018 - Regulatory press release

Stockholm, Sweden, February 21, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received approval by the Estonian State Agency ...

Full Year Report January – December 2017

February 20, 2018 - Regulatory press release

Successful IPO and continued positive result for BioArctic. October – December 2017. Net sales for the period amounted to SEK 51.0 million (94.4). Operating profit amounted ...

Invitation to presentation of BioArctic’s Full Year Report 2017 on February 20, 2018

February 5, 2018 - Regulatory press release

Stockholm, Sweden, February 5, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Full Year Report 2017 for the period January – ...

BioArctic receives US patent protection for a method with a medical device for treatment of patients with Complete Spinal Cord Injury

February 2, 2018 - Regulatory press release

Stockholm, Sweden, February 2, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US Patent and Trademark Office (USPTO) published an Issue ...

Proud partner of: